These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 25592064)
1. Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells. Choi JE; Woo SM; Min KJ; Kang SH; Lee SJ; Kwon TK Oncol Rep; 2015 Mar; 33(3):1395-401. PubMed ID: 25592064 [TBL] [Abstract][Full Text] [Related]
2. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. Song JH; Kandasamy K; Kraft AS J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488 [TBL] [Abstract][Full Text] [Related]
3. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351 [TBL] [Abstract][Full Text] [Related]
4. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354 [TBL] [Abstract][Full Text] [Related]
5. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
6. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
8. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Okumura K; Huang S; Sinicrope FA Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028 [TBL] [Abstract][Full Text] [Related]
9. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737. Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105 [TBL] [Abstract][Full Text] [Related]
10. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124 [TBL] [Abstract][Full Text] [Related]
11. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Mazumder S; Choudhary GS; Al-Harbi S; Almasan A Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702 [TBL] [Abstract][Full Text] [Related]
12. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980 [TBL] [Abstract][Full Text] [Related]
13. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib. Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609 [TBL] [Abstract][Full Text] [Related]
14. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698 [TBL] [Abstract][Full Text] [Related]
15. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
16. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332 [TBL] [Abstract][Full Text] [Related]
18. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153 [TBL] [Abstract][Full Text] [Related]
19. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Olberding KE; Wang X; Zhu Y; Pan J; Rai SN; Li C Cancer Biol Ther; 2010 Nov; 10(9):918-29. PubMed ID: 20818182 [TBL] [Abstract][Full Text] [Related]
20. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Song JH; Kraft AS Cancer Res; 2012 Jan; 72(1):294-303. PubMed ID: 22080570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]